110 related articles for article (PubMed ID: 23127292)
1. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.
Coates AS; Millar EK; O'Toole SA; Molloy TJ; Viale G; Goldhirsch A; Regan MM; Gelber RD; Sun Z; Castiglione-Gertsch M; Gusterson B; Musgrove EA; Sutherland RL
Breast Cancer Res; 2012 Nov; 14(6):R143. PubMed ID: 23127292
[TBL] [Abstract][Full Text] [Related]
2. Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
Pagani O; Price KN; Gelber RD; Castiglione-Gertsch M; Holmberg SB; Lindtner J; Thürlimann B; Collins J; Fey MF; Coates AS; Goldhirsch A;
Breast Cancer Res Treat; 2009 Sep; 117(2):319-24. PubMed ID: 19137426
[TBL] [Abstract][Full Text] [Related]
3. Expression level of beta protein 1 mRNA in Chinese breast cancer patients: a potential molecular marker for poor prognosis.
Yu M; Yang Y; Shi Y; Wang D; Wei X; Zhang N; Niu R
Cancer Sci; 2008 Jan; 99(1):173-8. PubMed ID: 17999690
[TBL] [Abstract][Full Text] [Related]
4. ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.
Bado I; Pham E; Soibam B; Nikolos F; Gustafsson JÅ; Thomas C
Oncotarget; 2018 Apr; 9(32):22509-22522. PubMed ID: 29854295
[TBL] [Abstract][Full Text] [Related]
5. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai K; Hung MC; Yamaguchi H
Am J Cancer Res; 2016; 6(8):1609-23. PubMed ID: 27648353
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Androgen Receptor in Invasive Breast Cancer and Its Association with Clinicopathologic Features in East Azarbaijan Province of Iran: A Cross-Sectional Study.
Nikanfar A; Nikanfar M; Fakhrjou A
Int J Hematol Oncol Stem Cell Res; 2023 Jul; 17(3):186-193. PubMed ID: 37817975
[No Abstract] [Full Text] [Related]
7. New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer.
El Hejjioui B; Lamrabet S; Amrani Joutei S; Senhaji N; Bouhafa T; Malhouf MA; Bennis S; Bouguenouch L
Diagnostics (Basel); 2023 Jun; 13(11):. PubMed ID: 37296801
[TBL] [Abstract][Full Text] [Related]
8. Positive p53 Expression Is Associated with Primary Endocrine Therapy Resistance in Locally Advanced Stage Luminal B HER2-Negative Breast Cancer Patients: A Cross-Sectional Study in Indonesia.
Halim F; Azhar Y; Suwarman S; Wahjoepramono EJ; Hernowo B
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296690
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases.
Hurson AN; Abubakar M; Hamilton AM; Conway K; Hoadley KA; Love MI; Olshan AF; Perou CM; Garcia-Closas M; Troester MA
NPJ Breast Cancer; 2022 Jun; 8(1):74. PubMed ID: 35701440
[TBL] [Abstract][Full Text] [Related]
10. Information theory approaches to improve glioma diagnostic workflows in surgical neuropathology.
Cevik L; Landrove MV; Aslan MT; Khammad V; Garagorry Guerra FJ; Cabello-Izquierdo Y; Wang W; Zhao J; Becker AP; Czeisler C; Rendeiro AC; Véras LLS; Zanon MF; Reis RM; Matsushita MM; Ozduman K; Pamir MN; Ersen Danyeli A; Pearce T; Felicella M; Eschbacher J; Arakaki N; Martinetto H; Parwani A; Thomas DL; Otero JJ
Brain Pathol; 2022 Sep; 32(5):e13050. PubMed ID: 35014126
[TBL] [Abstract][Full Text] [Related]
11. TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study.
Hurson AN; Abubakar M; Hamilton AM; Conway K; Hoadley KA; Love MI; Olshan AF; Perou CM; Garcia-Closas M; Troester MA
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):124-131. PubMed ID: 34737209
[TBL] [Abstract][Full Text] [Related]
12. Integrated Bioinformatics and Experimental Approaches Identified the Role of NPPA in the Proliferation and the Malignant Behavior of Breast Cancer.
Sun A; Sheng X; Tang J; Yu Z; Zhang J
J Immunol Res; 2021; 2021():7876489. PubMed ID: 34616853
[TBL] [Abstract][Full Text] [Related]
13. ERα determines the chemo-resistant function of mutant p53 involving the switch between lincRNA-p21 and DDB2 expressions.
He YH; Yeh MH; Chen HF; Wang TS; Wong RH; Wei YL; Huynh TK; Hu DW; Cheng FJ; Chen JY; Hu SW; Huang CC; Chen Y; Yu J; Cheng WC; Shen PC; Liu LC; Huang CH; Chang YJ; Huang WC
Mol Ther Nucleic Acids; 2021 Sep; 25():536-553. PubMed ID: 34589276
[TBL] [Abstract][Full Text] [Related]
14. Role of Sex in the Therapeutic Targeting of p53 Circuitry.
Mancini F; Giorgini L; Teveroni E; Pontecorvi A; Moretti F
Front Oncol; 2021; 11():698946. PubMed ID: 34307167
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Kashyap D; Garg VK; Sandberg EN; Goel N; Bishayee A
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33920506
[TBL] [Abstract][Full Text] [Related]
16. Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment.
da Silva JL; Rodrigues FR; de Mesquita GG; Fernandes PV; Thuler LCS; de Melo AC
Breast Cancer (Dove Med Press); 2021; 13():31-44. PubMed ID: 33469357
[TBL] [Abstract][Full Text] [Related]
17. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.
Nguyen D; Yu J; Reinhold WC; Yang SX
JAMA Netw Open; 2020 Jul; 3(7):e207213. PubMed ID: 32644137
[TBL] [Abstract][Full Text] [Related]
18. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
[TBL] [Abstract][Full Text] [Related]
19. Association of TNFAIP8 gene polymorphisms with endometrial cancer in northern Chinese women.
Liu T; Jiang L; Yu L; Ge T; Wang J; Gao H
Cancer Cell Int; 2019; 19():105. PubMed ID: 31043860
[TBL] [Abstract][Full Text] [Related]
20. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis.
Ilie SM; Bacinschi XE; Botnariuc I; Anghel RM
Breast Cancer (Dove Med Press); 2018; 10():177-194. PubMed ID: 30538542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
